Experimental CAR-T injection targets Hard-to-Treat prostate cancer
NCT ID NCT07240857
First seen Nov 21, 2025 · Last updated Jun 14, 2026 · Updated 24 times
Summary
This early-phase study tests a new treatment called ACT#001 CAR-T cells for men with castration-resistant prostate cancer (CRPC) that has not responded to standard hormone therapy. The treatment is injected directly into the tumor area. The main goal is to check safety, and researchers will also measure if PSA levels drop by at least 50%. About 18 adults with PSMA-positive tumors are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER (CRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.